Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 668-674    DOI: 10.31083/j.ejgo.2020.05.5038
Original Research Previous articles | Next articles
The impact of pre-existing polycystic ovary syndrome on endometrial cancer recurrence
T. Uehara1, *(), A. Mitsuhashi1, M. Shozu1
1Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, Chuoku, Chiba, Japan
Download:  PDF(315KB)  ( 191 ) Full text   ( 26 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: Polycystic ovary syndrome (PCOS) is a risk factor for the development of endometrial cancer (EC). To the present authors’ knowledge, no study has clarified whether pre-existing PCOS is a prognostic factor for post-surgical EC recurrences. The aim of this study was to determine whether pre-existing PCOS is a risk factor for the recurrence of EC even after the surgical treatment of EC in premenopausal women. Materials and Methods: The authors performed a retrospective cohort study on premenopausal EC patients aged 50 years or younger who underwent surgery at this hospital between 2009 and 2013. The median follow-up period was 65.5 months. Results: Of 46 patients with EC, nine (19.6%) had PCOS. Four of the nine PCOS patients developed recurrence of EC, three of whom died of the disease, whereas only one of 37 patients who did not have PCOS developed EC recurrence (44.4% and 2.7%, respectively; p = 0.003). Univariate analysis showed that the progression-free and overall survival of the patients with pre-existing PCOS was worse than that of patients without pre-existing PCOS (p = 0.008 and p = 0.029, respectively). Multivariate analysis revealed that PCOS was a poor prognostic factor for progression-free survival and a marginal poor prognostic factor for overall survival (p = 0.011 and p = 0.061, respectively). Conclusions: Pre-existing PCOS was a risk factor for recurrence in premenopausal post-operative patients with EC aged 50 years or younger.
Key words:  Polycystic ovary syndrome      Endometrial neoplasm      Recurrence      Premenopause      Insulin resistance     
Submitted:  27 January 2019      Accepted:  01 April 2019      Published:  15 October 2020     
*Corresponding Author(s):  TAKASHI UEHARA     E-mail:  takuehar@chiba-u.jp

Cite this article: 

T. Uehara, A. Mitsuhashi, M. Shozu. The impact of pre-existing polycystic ovary syndrome on endometrial cancer recurrence. European Journal of Gynaecological Oncology, 2020, 41(5): 668-674.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5038     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/668

[1] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[2] S. H. Chung, J. H. Sang. Is there a difference between synchronous multiple primary cancer and metastasis cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 480-483.
[3] H. Cokmez, A. Yilmaz. Concordance of preoperative and postoperative histological grades in endometrioid type endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 208-213.
[4] Z. Zheng, Z.H. Han, Z.T. Li, X.H. Wu. The impact of laparoscopic surgical treatments on oncologic outcome of Stage I uterine leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 977-981.
[5] R. Tinelli, S. Guicciardini, S. Uccella, E. Cicinelli, F. Romano, G. Trojano. A rare case of false positive metastatic nodes detected at PET/CT scan six months after the laparoscopic treatment of a patient with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1039-1040.
[6] F.V. Carvalho Sousa Esteves, L.A. Gomes de Sousa, R.S. Martins, A.L. Ramos Bezerra de Alencar, L. de Deus Sousa, M.C. Cronemberger Guimarães Serzedo, I. Meneses de Carvalho Coelho, S.C. Vieira. Paget’s disease of the breast after nipple-areola sparing mastectomy: case report[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1087-1090.
[7] N. Kosaka, K. Hasegawa, K. Kiuchi, S. Ochiai, E. Motegi, I. Fukasawa. Two cases of recurrent small-cell carcinoma of the uterine cervix treated with amrubicin as salvage chemotherapy[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1100-1103.
[8] S. Bertozzi, A. P. Londero, S. Bernardi, C. Cedolini. Applicability of the Notthingham Prognostic Index for predicting the survival of triple-negative invasive breast cancer in a single Italian center[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 787-790.
[9] R. Du, L. Li, S. Ma, X. Tan, S. Zhong, M. Wu. Survival outcomes of Stage IB cervical cancer treated with standard radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 810-814.
[10] F. El-Sharkawy, M. Sittig, C. Nieroda, A. Sardi. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent mucinous cystadenoma of the ovary[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 543-546.
[11] E. Lajtman, M. Mlynček, T. Kapusta, M. Kubalová. The value of gynecological cancer follow-up: a 15-year single institutional experience[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 619-627.
[12] Z. Marchocki, L.A. Norris, F. Abu Saadeh, N. Gleeson. Recurrence of venous thromboembolism in patients with gynaecological malignancies: incidence, risk factors, and impact on survival[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 413-419.
[13] D. Odetto, M.C. Saez, A. Wernicke, J. Saadi, F. Noll, M. Perrotta. Low-risk endometrial carcinoma: is it time to subclassify it?[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 447-451.
[14] Xin Yan, Yu-Nong Gao, Quan Bao, Na An, Min Gao, Hong Zheng. Hepatic resection for recurrent metastatic ovarian carcinoma or peritoneal carcinoma: a retrospective case-control study[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 113-118.
[15] S. Stanosz, J. von Mach Szczypiński, A. Fogel, E. Sowińska-Przepiera, J. Kościuszkiewicz, E. Żochowska, A. Syrenicz. Concentration of serotonin in perimenopausal women with ductal breast cancer and polycystic ovary syndrome[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 884-888.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38 -46 .
[3] Richard W. Nesto. The Relation of Insulin Resistance Syndromes to Risk of Cardiovascular Disease[J]. Reviews in Cardiovascular Medicine, 2003, 4(S6): 11 -18 .
[4] Akanksha Agrawal, Deepanshu Jain, Pradhum Ram, Jorge Luis Penalver Leon, Janani Rangaswami. Anticoagulation for intra-cardiac thrombi in peripartum cardiomyopathy: A review of the literature[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 53 -58 .
[5] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[6] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[7] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[8] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[9] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[10] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .